Lipids and Warfarin Requirements

Thromb Haemost 1990; 63(01): 148-149
DOI: 10.1055/s-0038-1645708

Letter to the Editor

Schattauer GmbH Stuttgart

A Robinson

Departments of Clinical Biochemistry, Haematology and Clinical Pharmacology, Llandough Hospital, Penarth, S. Glam, UK

,

F O Liau

Departments of Clinical Biochemistry, Haematology and Clinical Pharmacology, Llandough Hospital, Penarth, S. Glam, UK

,

P A Routledge

Departments of Clinical Biochemistry, Haematology and Clinical Pharmacology, Llandough Hospital, Penarth, S. Glam, UK

,

G Backhouse

Departments of Clinical Biochemistry, Haematology and Clinical Pharmacology, Llandough Hospital, Penarth, S. Glam, UK

,

B P Spragg

Departments of Clinical Biochemistry, Haematology and Clinical Pharmacology, Llandough Hospital, Penarth, S. Glam, UK

,

D P Bentley

Departments of Clinical Biochemistry, Haematology and Clinical Pharmacology, Llandough Hospital, Penarth, S. Glam, UK

References
1 Nikkila EA, Pelkonen R. Serum lipid-reducing agents and anticoagulant requirements. Lancet 1963; I: 332
2 Bentley DP, Backhouse G, Hutchings A, Hadden RL, Spragg B, Routledge PA. Investigation of patients with abnormal response to warfarin. Br J Clin Pharmac 1986; 22: 37-41
3 Bjornsson TD, Blaschke T, Meffin P. High performance liquid chromatographic analysis of drugs in biological fluids; (1) Warfarin. J Pharmacol Sci 1977; 66: 142-144
4 Nikkila EO, Pelkonen R. Serum tocopherol, cholesterol and triglyceride in coronary heart disease. Circulation 1963; 27: 919-928
5 Mann JI, Lewis B, Shepherd J, Winder AF, Fenster S, Rose L, Margan B. Blood lipid concentrations and other cardiovascular risk factors: distribution prevalence and detection in Britain. Br Med J 1988; 296: 1702-1706
6 Simpson HC R, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; i: 786-790